FY2024 EPS Estimates for BioCardia Boosted by HC Wainwright

BioCardia, Inc. (NASDAQ:BCDA) – Stock analysts at HC Wainwright increased their FY2024 earnings per share estimates for shares of BioCardia in a research report issued to clients and investors on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($3.52) per share for the year, up from their prior estimate of ($5.06). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for BioCardia’s current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for BioCardia’s Q4 2024 earnings at ($0.87) EPS, FY2025 earnings at ($1.22) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.42) EPS and FY2028 earnings at ($1.03) EPS.

BioCardia Stock Up 10.8 %

BCDA stock opened at $2.05 on Monday. The company has a 50-day simple moving average of $2.58 and a 200 day simple moving average of $3.27. The company has a market capitalization of $4.35 million, a P/E ratio of -0.49 and a beta of 1.28. BioCardia has a fifty-two week low of $1.84 and a fifty-two week high of $11.55.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.